Actionable news
0
All posts from Actionable news
Actionable news in LBIO: LION BIOTECHNOLOGIES Inc COMMON STOCK,

Additional definitive proxy soliciting materials and Rule 14(a)(12) material

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934

Filed by the Registrant x

Filed by a Party other than the Registrant o

Check the appropriate box:

o Preliminary Proxy Statement
o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
o Definitive Proxy Statement
x Definitive Additional Materials
o Soliciting Material Pursuant to §240.14a-12

LION BIOTECHNOLOGIES, INC.

(Name of Registrant as Specified In Its Charter)

Payment of Filing Fee (check the appropriate box);

(1) Title of each class of securities to which transaction applies:
(2) Aggregate number of securities to which transaction applies:
(3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
(4) Proposed maximum aggregate value of transaction:
(5) Total fee paid:
o Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever Lion Biotechnologies, Inc. makes a similar move, sign up!

Other recent filings from the company include the following:

Lion Biotechnologies, Inc.'s Chief Medical Officer was just granted 225,000 options - April 21, 2016
Lion Biotechnologies, Inc.'s Chief Medical Officer just declared ownership of no shares of Lion Biotechnologies, Inc. - April 21, 2016
Changes in Registrants Certifying - April 7, 2016